LiPlasome Pharma strives to increase survival and improve the quality of life for cancer patients. We are aiming to develop a novel lipid delivery concept to increase the effect of active anticancer drugs and to reduce side effects.

The most advanced drug in LiPlasome's pipeline is LiPlaCis® (cisplatin in a new liposomal reformulation) which has shown proof-of-concept in pre-clinical studies and which is in a phase 1 dose escalating trial. Cisplatin is one of the most commonly used drugs to treat cancer.

A screening program - to select “high likelihood responding patients” to be included in extension phase 1/phase 2 - has been initiated in collaboration with Danish Breast Cancers Cooperative Group (DBCG) and Medical Prognosis Institute (MPI), Hoersholm, Denmark.